Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy

Daisuke Ogiya, MD PhD, Lisa Müller, Sigitas J Verselis, PhD, Heiner Schaal, PhD, Ivane Abiatari, MD, Ana M Stenstrom, Catherine A Nicholas, John F Daley, Michael P. Chu, David M. Dorfman, MD PhD, Linda M. Pilarski, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Sophia Adamia, PhD

Blood (2019) 134 (Supplement_1): 1804.

https://doi.org/10.1182/blood-2019-131775

Published: 2019

Journal Articles

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

Jana Jakubikova, Sophia Adamia, Maria Kost-Alimova, Steffen Klippel, David Cervi, John F. Daley, Dana Cholujova, Sun-Young Kong, Merav Leiba, Simona Blotta, Melissa Ooi, Jake Delmore, Jacob Laubach, Paul G. Richardson, Jan Sedlak, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2011) 117 (17): 4409–4419.

https://doi.org/10.1182/blood-2010-02-267344

Published: 2011

Includes: Supplemental data

Journal Articles

Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma

Rao H. Prabhala, Dheeraj Pelluru, Mariateresa Fulciniti, Harsha K. Prabhala, Puru Nanjappa, Weihua Song, Christine Pai, Samir Amin, Yu-Tzu Tai, Paul G. Richardson, Irene M. Ghobrial, Steven P. Treon, John F. Daley, Kenneth C. Anderson, Jeffery L. Kutok, Nikhil C. Munshi

Blood (2010) 115 (26): 5385–5392.

https://doi.org/10.1182/blood-2009-10-246660

Published: 2010

Journal Articles

Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.

Jana Jakubikova, David N. Cervi, John F. Daley, Danka Cholujova, Melissa G. Ooi, Steffen Klippel, Simona Blotta, Merav Leiba, Jake Delmore, Douglas McMillin, Efstathios Kastritis, Jacob Laubach, Paul Richardson, Jan Sedlak, Kenneth C. Anderson, Constantine S. Mitsiades, M.D., Ph.D

Blood (2009) 114 (22): 954.

https://doi.org/10.1182/blood.V114.22.954.954

Published: 2009

Journal Articles

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells

Blood (2008) 112 (13): 5161–5170.

https://doi.org/10.1182/blood-2008-02-138065

Published: 2008

Includes: Supplemental data

Journal Articles

TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application

Rao Prabhala, PhD, Dheeraj Pelluru, Mariateresa Fulciniti, Puru Nanjappa, Harsha K. Prabhala, Nithya S. Prabhala, Constantine Mitsiades, Yu-Tzu Tai, Irene Ghobrial, Paul Richardson, Konstantinos Lefkimmiatis, John F. Daley, Yvonne A. Efebera, Kenneth C. Anderson, MD, Nikhil C. Munshi

Blood (2008) 112 (11): 2737.

https://doi.org/10.1182/blood.V112.11.2737.2737

Published: 2008

Journal Articles

T H 17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma.

Rao Prabhala, PhD, Dheeraj Pelluru, PhD, Paola Neri, MD, Mariateresa Fulciniti, PhD, James J. Driscoll, MD, PhD, Song Weihua, MD, Simona Blotta, MD, Yu-Tzu Tai, PhD, Hiren Patel, BS, Yvonne A. Efebera, MD, Teru Hideshima, MD, PhD, Dhaminder Chauhan, PhD, John F. Daley, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2007) 110 (11): 3517.

https://doi.org/10.1182/blood.V110.11.3517.3517

Published: 2007

Journal Articles

Myeloma Microenvironment Controls T Regulatory Cell Activity: Potential Target for Therapeutic Interventions.

Rao H. Prabhala, PhD, Paola Neri, MD, Mariateresa Fulciniti, PhD, Vanessa A. Therrien, Vidit Munshi, James J. Driscoll, MD,PhD, Masood A. Shammas, PhD, Teru Hideshima, MD,PhD, John F. Daley, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2006) 108 (11): 659.

https://doi.org/10.1182/blood.V108.11.659.659

Published: 2006

Journal Articles

Dysfunctional T regulatory cells in multiple myeloma

Rao H. Prabhala, Paola Neri, Jooeun E. Bae, Pierfrancesco Tassone, Masood A. Shammas, Charles K. Allam, John F. Daley, Dharminder Chauhan, Elizabeth Blanchard, Hemant S. Thatte, Kenneth C. Anderson, Nikhil C. Munshi

Blood (2006) 107 (1): 301–304.

https://doi.org/10.1182/blood-2005-08-3101

Published: 2006

Journal Articles

Dysfunctional T Regulatory Cells in Myeloma: Molecular Mechanisms of Dysregulation.

Rao H. Prabhala, PhD, Paola Neri, MD, Pierfrancesco Tassone, MD, Jooeun E. Bae, PhD, Masood A. Shammas, PhD, John F. Daley, PhD, Weihua Song, MD, Robert Bertheau, MD, Dharminder Chauhan, PhD, Ramesh B. Bachu, PhD, Hemant Thatte, PhD, Kenneth Anderson, MD, Nikhil C. Munshi, MD

Blood (2005) 106 (11): 3462.

https://doi.org/10.1182/blood.V106.11.3462.3462

Published: 2005

Journal Articles

Dysregulated CD4 + CD25 + T- Regulatory Cells and TLRs in Myeloma.

Rao Prabhala, PhD, Paola Neri, MD, Pierfrancesco Tassone, MD, Masood A. Shammas, PhD, Jooeun Bae, PhD, Virginia M. Cumming, Charles K. Allam, MD, John F. Daley, PhD, Frank Desarneud, PhD, Dharminder Chauhan, PhD, Elizabeth Blanchard, MD, Kenneth Anderson, MD, Nikhil C. Munshi, MD

Blood (2004) 104 (11): 2466.

https://doi.org/10.1182/blood.V104.11.2466.2466

Published: 2004

Journal Articles

Expression of the CD8αβ-Heterodimer on CD8 + T Lymphocytes in Peripheral Blood Lymphocytes of Human Immunodeficiency Virus − and Human Immunodeficiency Virus + Individuals

Jörn E. Schmitz, Meryl A. Forman, Michelle A. Lifton, Orlando Concepción, Jr, Keith A. Reimann, Clyde S. Crumpacker, John F. Daley, Rebecca S. Gelman, Norman L. Letvin

Blood (1998) 92 (1): 198–206.

https://doi.org/10.1182/blood.V92.1.198.413k13_198_206

Published: 1998

NARROW

Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma

Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells

TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application

T H 17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma.

Myeloma Microenvironment Controls T Regulatory Cell Activity: Potential Target for Therapeutic Interventions.

Dysfunctional T regulatory cells in multiple myeloma

Dysfunctional T Regulatory Cells in Myeloma: Molecular Mechanisms of Dysregulation.

Dysregulated CD4 + CD25 + T- Regulatory Cells and TLRs in Myeloma.

Expression of the CD8αβ-Heterodimer on CD8 + T Lymphocytes in Peripheral Blood Lymphocytes of Human Immunodeficiency Virus − and Human Immunodeficiency Virus + Individuals

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only